Publications
Zeige Ergebnisse 1 - 17 von 17
Kautzky-Willer A, Stich K, Hintersteiner J, Kautzky A, Kamyar M-R, Saukel J et al. Sex-specific-differences in cardiometabolic risk in type 1 diabetes: a cross-sectional study. Cardiovascular Diabetology . 2013;12:78. doi: 10.1186/1475-2840-12-78
Lemmens R, Hahnenkamp C, Gössmann U, Harreiter J, Kamyar M-R, Johnson BJ et al. Evaluation of educational needs in patients with diabetes mellitus in respect of medication use in Austria. International Journal of Clinical Pharmacy. 2012;34(3):490-500. doi: 10.1007/s11096-012-9636-0
Handisurya A, Bancher-Todesca D, Kamyar M-R, Lemmens R, Kautzky-Willer A. Clinical characteristics, modalities and complications of diabetic patients with migration background at a Central European University Clinic. Wiener Medizinische Wochenschrift. 2011;161(5-6):128-135. doi: 10.1007/s10354-011-0870-1
Kautzky-Willer A, Kamyar M-R, Gerhat D, Handisurya A, Stemer G, Hudson SA et al. Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus. Gender Medicine. 2010 Dez;7(6):571-583. doi: 10.1016/j.genm.2010.12.001
Nemec K, Timin E, Kamyar M-R, Lemmens R. Evidence-based intravenous pain treatment with analgesic infusion regimens. Arzneimittel-Forschung. 2010;60(5):256-261.
Nemec K, Cihal P, Timin E, Lemmens R, Kamyar M-R. Analgesic infusions in a general hospital- old habits and tradition or drug therapy on evidence-based standards? Development of prescribing guidelines for intravenous combinations in the treatment of pain. Pharmacy World and Science: international journal of clinical pharmacy and pharmaceutical care. 2009 Feb;31(1):40–141. doi: 10.1007/s11096-008-9262-z
Lemmens R, Kamyar M-R, Dornetshuber-Fleiss R. Cyclodepsipeptides - potential drugs and lead compounds in the drug development process. Current Medicinal Chemistry. 2009;(16):1122-1137.
Dornetshuber R, Kamyar MR, Rawnduzi P, Baburin I, Kouri K, Pilz P et al. Effects of the anthelmintic drug PF1022A on mammalian tissue and cells. Biochemical Pharmacology. 2009;77(8):1437-1444. doi: 10.1016/j.bcp.2009.01.005
Lemmens R, Kamyar M-R, Johnson BJ, Hudson SA, McAnaw JJ. Adherence to clinical guidelines in the prevention of coronary heart disease in type II diabetes mellitus. Pharmacy World and Science: international journal of clinical pharmacy and pharmaceutical care. 2008;30(1):136-143.
Kamyar M-R, Johnson BJ, McAnaw JJ, Lemmens R, Hudson SA. Evaluation of the implementation of medication guidelines in the prevention of coronary heart disease for patients with type II diabetes mellitus in primary care: Evaluation of the implementation of medication guidelines in the prevention of coronary heart disease for patients with type II diabetes mellitus in primary care. Pharmacy World and Science: international journal of clinical pharmacy and pharmaceutical care. 2008.
Dornetshuber-Fleiss R, Heffeter P, Kamyar M-R, Peterbauer T, Berger W, Lemmens R. Enniatin exerts p53-dependent cytostatic and p53-independent cytotoxic activities against human cancer cells: Enniatin exerts p53-dependent cytostatic and p53-independent cytotoxic activities against human cancer cells. Chemical Research in Toxicology. 2007;20(3):465-473.
Kamyar M-R, Kouri K, Rawnduzi P, Studenik C, Lemmens R. Effects of moniliformin in presence of cyclohexadepsipeptides on isolated mammalian tissue and cells. Toxicology in Vitro. 2006;20(8):1284-1291. doi: 10.1016/j.tiv.2006.03.001
Galanski M, Erker T, Handler N, Lemmens R, Kamyar M-R, Studenik C. Studies on the chemistry of thienoanellated O,N- and S,N-containing heterocycles. Part 30: Synthesis and pharmacological properties of thieno[2,3-b][1,4]thiazines with potential vasopressin receptor antagonistic activity. Bioorganic & Medicinal Chemistry. 2006;14(3):826-836. doi: 10.1016/j.bmc.2005.09.001
Lemmens R, Kamyar M-R. Vasopressin antagonists. Cellular and Molecular Life Sciences. 2006;63(15):1766-1779. doi: 10.1007/s00018-006-6054-2
Galanski M, Erker T, Studenik C, Kamyar M-R, Rawnduzi P, Pabstova M et al. Synthesis and pharmacological profile of non-peptide vasopressin antagonists. European Journal of Pharmaceutical Sciences. 2005;24(5):421-431. doi: 10.1016/j.ejps.2004.12.008
Kamyar M-R, Rawnduzi P, Studenik C, Kouri K, Lemmens R. Investigation of the electrophysiological properties of enniatins. Archives of Biochemistry and Biophysics. 2004;429(2):215-223. doi: 10.1016/j.abb.2004.06.013
Kouri K, Kamyar M-R, Lemmens R. Actions of the antibiotic mycotoxins beauvericin and enniatin on mammalian tissue. Forum of Nutrition. 2003;56:413-414.
Zeige Ergebnisse 1 - 17 von 17